Loading...
Docoh

Ikena Oncology (IKNA)

Employees
Data from SEC filings
Employee count
ESG framework mentions
In last year of SEC filings
Sustainability Accounting Standards Board (SASB)
No mentions
Global Reporting Initiative (GRI)
No mentions
Task Force on Climate-related Financial Disclosures (TCFD)
No mentions
UN Sustainable Development Goals (SDGs)
No mentions
Shareholder alignment
Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM
Ikena Oncology, Inc., a Delaware corporation (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”) on June 9, 2022. As of April 14, 2022, the record date for the Annual Meeting, there were 29,947,826 outstanding shares of the Company’s voting common stock. The Company’s stockholders voted on the following matters, which are described in detail in the Company’s Definitive Proxy Statement filed with the U.S. Securities and Exchange Commission on April 27, 2022: (i) to elect three directors, Iain D. Dukes, D.Phil, Maria Koehler, M.D., and Otello Stampacchia, Ph. D., as Class I directors of the Company to serve for a three-year term expiring at the Company’s 2025 annual meeting of stockholders and until their successor has been duly elected and qualified, subject to their earlier death, resignation or removal (“Proposal 1”) and (ii) to ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022 (“Proposal 2”).
The Company’s stockholders approved the Class I director nominees, Iain D. Dukes, D.Phil, Maria Koehler, M.D., and Otello Stampacchia, Ph. D., recommended for election in Proposal 1 at the Annual Meeting. The votes cast at the Annual Meeting were as follows:

ForWithheldBroker Non-Votes
Iain D. Dukes, D.Phil23,863,7342,147,3372,466,970
Maria Koehler, M.D.24,597,9501,413,1212,466,970
Otello Stampacchia, Ph. D.23,333,2762,677,7952,466,970
The Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022, recommended for ratification in Proposal 2 at the Annual Meeting. The votes cast at the Annual Meeting were as follows:

ForAgainstAbstainBroker Non-Votes
28,476,5241,0954220
No other matters were submitted to or voted on by the Company’s stockholders at the Annual Meeting.